Siqiang Niu1, Jie Wei2, Chunhong Zou3, Kalyan D Chavda4, Jingnan Lv5, Haifang Zhang5, Hong Du5, Yi-Wei Tang6, Johann D D Pitout7, Robert A Bonomo8,9,10, Barry N Kreiswirth4, Liang Chen4. 1. Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. The Key Laboratory of Molecular Biology of Infectious Diseases designated by the Chinese Ministry of Education, Chongqing Medical University, Chongqing, China. 3. College of Laboratory Medicine, Chongqing Medical University, Chongqing, China. 4. Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ, USA. 5. Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. 6. Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, USA. 7. University of Calgary, Calgary, Alberta, Canada. 8. Case VA Center for Antimicrobial Resistance and Epidemiology (CARES), Cleveland, OH, USA. 9. Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA. 10. Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Abstract
OBJECTIVES: To examine the in vitro selection of aztreonam/avibactam resistance among MBL-producing Klebsiella pneumoniae and to understand the mechanism of increased resistance. METHODS: The MICs of aztreonam were determined with and without avibactam (4 mg/L) using a broth microdilution method. Single-step and multi-step mutant selection was conducted on five MBL-producing K. pneumoniae strains, including two dual carbapenemase producers. Genomic sequencing and gene cloning were performed to investigate the mechanism of increased resistance. RESULTS: We examined the MICs for 68 MBL-producing K. pneumoniae isolates, including 13 dual carbapenemase producers. Compared with aztreonam alone, the addition of avibactam (4 mg/L) reduced the MICs for all isolates by >128-fold, with MIC50 and MIC90 values of 0.25 and 1 mg/L, respectively. One NDM-1-, OXA-48-, CTX-M-15- and CMY-16-positive ST101 K. pneumoniae strain was selected to be resistant to aztreonam/avibactam, with a >16-fold increase in MIC (>128 mg/L). WGS revealed that the resistant mutants lost the blaNDM-1 gene, but acquired amino acid substitutions in CMY-16 (Tyr150Ser and Asn346His). Construction of blaCMY-16 mutants confirmed that the substitutions (Tyr150Ser and Asn346His) were primarily responsible for the decreased susceptibility to aztreonam/avibactam. In addition, transfer of blaCMY-16 mutant (Tyr150Ser and Asn346His) plasmid constructs into certain clinical carbapenemase-producing isolates demonstrated >64-fold increased MICs of aztreonam/avibactam and aztreonam/avibactam/ceftazidime. CONCLUSIONS: Aztreonam in combination with avibactam showed potent in vitro activity against MBL-producing K. pneumoniae. However, our study suggested the likelihood of aztreonam/avibactam resistance among MBL- and AmpC-co-producing strains and clinical practice should beware of the possibility of the emerging resistance.
OBJECTIVES: To examine the in vitro selection of aztreonam/avibactam resistance among MBL-producing Klebsiella pneumoniae and to understand the mechanism of increased resistance. METHODS: The MICs of aztreonam were determined with and without avibactam (4 mg/L) using a broth microdilution method. Single-step and multi-step mutant selection was conducted on five MBL-producing K. pneumoniae strains, including two dual carbapenemase producers. Genomic sequencing and gene cloning were performed to investigate the mechanism of increased resistance. RESULTS: We examined the MICs for 68 MBL-producing K. pneumoniae isolates, including 13 dual carbapenemase producers. Compared with aztreonam alone, the addition of avibactam (4 mg/L) reduced the MICs for all isolates by >128-fold, with MIC50 and MIC90 values of 0.25 and 1 mg/L, respectively. One NDM-1-, OXA-48-, CTX-M-15- and CMY-16-positive ST101 K. pneumoniae strain was selected to be resistant to aztreonam/avibactam, with a >16-fold increase in MIC (>128 mg/L). WGS revealed that the resistant mutants lost the blaNDM-1 gene, but acquired amino acid substitutions in CMY-16 (Tyr150Ser and Asn346His). Construction of blaCMY-16 mutants confirmed that the substitutions (Tyr150Ser and Asn346His) were primarily responsible for the decreased susceptibility to aztreonam/avibactam. In addition, transfer of blaCMY-16 mutant (Tyr150Ser and Asn346His) plasmid constructs into certain clinical carbapenemase-producing isolates demonstrated >64-fold increased MICs of aztreonam/avibactam and aztreonam/avibactam/ceftazidime. CONCLUSIONS:Aztreonam in combination with avibactam showed potent in vitro activity against MBL-producing K. pneumoniae. However, our study suggested the likelihood of aztreonam/avibactam resistance among MBL- and AmpC-co-producing strains and clinical practice should beware of the possibility of the emerging resistance.
Authors: Anton Bankevich; Sergey Nurk; Dmitry Antipov; Alexey A Gurevich; Mikhail Dvorkin; Alexander S Kulikov; Valery M Lesin; Sergey I Nikolenko; Son Pham; Andrey D Prjibelski; Alexey V Pyshkin; Alexander V Sirotkin; Nikolay Vyahhi; Glenn Tesler; Max A Alekseyev; Pavel A Pevzner Journal: J Comput Biol Date: 2012-04-16 Impact factor: 1.479
Authors: Jaimie Mittal; Wendy A Szymczak; Yi Guo; Michael H Levi; Liang Chen; Barry N Kreiswirth; Paul F Riska; Priya Nori Journal: BMJ Case Rep Date: 2018-07-18
Authors: Helio S Sader; Mariana Castanheira; Dee Shortridge; Rodrigo E Mendes; Robert K Flamm Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Evelyn Shaw; Alexander Rombauts; Fe Tubau; Ariadna Padullés; Jordi Càmara; Toni Lozano; Sara Cobo-Sacristán; Núria Sabe; Imma Grau; Raül Rigo-Bonnin; M Angeles Dominguez; Jordi Carratalà Journal: J Antimicrob Chemother Date: 2018-04-01 Impact factor: 5.790
Authors: Olga Lomovskaya; Dongxu Sun; Debora Rubio-Aparicio; Kirk Nelson; Ruslan Tsivkovski; David C Griffith; Michael N Dudley Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Michelle Lowe; Marleen M Kock; Jennifer Coetzee; Ebrahim Hoosien; Gisele Peirano; Kathy-Ann Strydom; Marthie M Ehlers; Nontombi M Mbelle; Elena Shashkina; David B Haslam; Puneet Dhawan; Robert J Donnelly; Liang Chen; Barry N Kreiswirth; Johann D D Pitout Journal: Emerg Infect Dis Date: 2019-04 Impact factor: 6.883